Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
종양용해성 바이러스 면역치료 시장 : 조사 범위
TMR사의 조사 보고서 세계 종양용해성 바이러스 면역치료 시장은 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사했습니다. 본 보고서는 2023년을 기준년, 2031년을 예측년으로, 2017년부터 2031년까지 세계 종양용해성 바이러스 면역치료 시장의 수익과 예측을 제공합니다. 또한 2023년부터 2031년까지 세계 종양용해성 바이러스 면역치료 시장의 복합 연간 성장률(CAGR)도 제공합니다.
이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 종양용해성 바이러스 면역치료 시장을 이해했습니다.
| 시장 현황 |
| 2022년 시장가치 |
1억 1,020만 달러 |
| 2031년 시장가치 |
5억 7,220만 달러 |
| 복합 연간 성장률(CAGR) |
21.1% |
이 보고서는 세계 종양용해성 바이러스 면역치료 시장 경쟁 구도를 조사했습니다. 세계 종양용해성 바이러스 면역요법 시장에서 사업을 전개하는 주요 기업이 확인되고, 이들 각 기업은 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT는 본 보고서에 소개된 세계 종양용해성 바이러스 면역치료 시장의 선수의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약: 시장
제4장 시장 개요
- 소개
- 시장 개요
- 시장 역학
- 시장 분석과 예측(2017년-2031년)
제5장 주요 인사이트
- 파이프라인 분석
- 주요 제품/브랜드 분석
- 주요 M&A
- COVID-19 팬데믹의 산업에 대한 영향
제6장 시장 분석과 예측 : 유형별
- 소개 및 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 유형별(2017년-2031년)
- 단순 헤르페스 바이러스
- 백신 바이러스
- 아데노바이러스
- 레오바이러스
- 기타
- 시장 매력도 분석 : 유형별
제7장 시장 분석과 예측 : 투여 경로별
- 소개 및 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 투여 경로별(2017년-2031년)
- 시장 매력도 분석 : 투여 경로별
제8장 시장 분석과 예측 : 용도별
- 소개 및 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 용도별(2017년-2031년)
- 흑색종
- 비소세포폐암(NSCLC)
- 췌장암
- 유방암
- 기타
- 시장 매력도 분석 : 투여 경로별
제9장 시장 분석과 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별(2017년-2031년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 시장 매력도 분석 :지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 예측
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 구도
- 시장 경쟁 매트릭스(티어별, 기업 규모별)
- 시장 점유율 분석 : 기업별(2022년)
- 기업 프로파일
- Amgen Inc.
- Merck & Co., Inc.(Viralytics Limited)
- Shanghai Sunway Biotech Co., Ltd.
- TILT Biotherapeutics
- Oncorus, Inc.
- Replimune Group, Inc.
- Oncolys Biopharma, Inc.
- Sorrento Therapeutics, Inc.
- Oncolytics Biotech, Inc.
- SillaJen, Inc.
BJH
Oncolytic Virus Immunotherapy Market - Scope of Report
TMR's report on the global oncolytic virus immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oncolytic virus immunotherapy market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the oncolytic virus immunotherapy market.
| Market Snapshot |
|---|
| Market Value in 2022 | US$ 110.2 Mn |
| Market Value in 2031 | US$ 572.2 Mn |
| CAGR | 21.1% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oncolytic virus immunotherapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oncolytic virus immunotherapy market.
The report delves into the competitive landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oncolytic virus immunotherapy market profiled in this report.
Key Questions Answered in Global oncolytic virus immunotherapy Market Report:
- What is the sales/revenue generated by oncolytic virus immunotherapy across all regions during the forecast period?
- What are the opportunities in the global oncolytic virus immunotherapy market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Oncolytic Virus Immunotherapy Market - Research Objectives and Research Approach
The comprehensive report on the global oncolytic virus immunotherapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global oncolytic virus immunotherapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oncolytic virus immunotherapy market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncolytic Virus Immunotherapy Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Herpes Simplex Virus
- 6.3.2. Vaccinia Virus
- 6.3.3. Adenovirus
- 6.3.4. Reovirus
- 6.3.5. Others
- 6.4. Market Attractiveness Analysis, by Type
7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Intratumoral
- 7.3.2. Intravenous
- 7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Application, 2017-2031
- 8.3.1. Melanoma
- 8.3.2. Non-small Cell Lung Cancer (NSCLC)
- 8.3.3. Pancreatic Cancer
- 8.3.4. Breast Cancer
- 8.3.5. Others
- 8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Type, 2017-2031
- 10.3.1. Herpes Simplex Virus
- 10.3.2. Vaccinia Virus
- 10.3.3. Adenovirus
- 10.3.4. Reovirus
- 10.3.5. Others
- 10.4. Market Value Forecast, by Route of Administration, 2017-2031
- 10.4.1. Intratumoral
- 10.4.2. Intravenous
- 10.5. Market Value Forecast, by Application, 2017-2031
- 10.5.1. Melanoma
- 10.5.2. Non-small Cell Lung Cancer (NSCLC)
- 10.5.3. Pancreatic Cancer
- 10.5.4. Breast Cancer
- 10.5.5. Others
- 10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Type
- 10.7.2. By Route of Administration
- 10.7.3. By Application
- 10.7.4. By Country
11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Type, 2017-2031
- 11.3.1. Herpes Simplex Virus
- 11.3.2. Vaccinia Virus
- 11.3.3. Adenovirus
- 11.3.4. Reovirus
- 11.3.5. Others
- 11.4. Market Value Forecast, by Route of Administration, 2017-2031
- 11.4.1. Intratumoral
- 11.4.2. Intravenous
- 11.5. Market Value Forecast, by Application, 2017-2031
- 11.5.1. Melanoma
- 11.5.2. Non-small Cell Lung Cancer (NSCLC)
- 11.5.3. Pancreatic Cancer
- 11.5.4. Breast Cancer
- 11.5.5. Others
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Type
- 11.7.2. By Route of Administration
- 11.7.3. By Application
- 11.7.4. By Country/Sub-region
12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Type, 2017-2031
- 12.3.1. Herpes Simplex Virus
- 12.3.2. Vaccinia Virus
- 12.3.3. Adenovirus
- 12.3.4. Reovirus
- 12.3.5. Others
- 12.4. Market Value Forecast, by Route of Administration, 2017-2031
- 12.4.1. Intratumoral
- 12.4.2. Intravenous
- 12.5. Market Value Forecast, by Application, 2017-2031
- 12.5.1. Melanoma
- 12.5.2. Non-small Cell Lung Cancer (NSCLC)
- 12.5.3. Pancreatic Cancer
- 12.5.4. Breast Cancer
- 12.5.5. Others
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Type
- 12.7.2. By Route of Administration
- 12.7.3. By Application
- 12.7.4. By Country/Sub-region
13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Type, 2017-2031
- 13.3.1. Herpes Simplex Virus
- 13.3.2. Vaccinia Virus
- 13.3.3. Adenovirus
- 13.3.4. Reovirus
- 13.3.5. Others
- 13.4. Market Value Forecast, by Route of Administration, 2017-2031
- 13.4.1. Intratumoral
- 13.4.2. Intravenous
- 13.5. Market Value Forecast, by Application, 2017-2031
- 13.5.1. Melanoma
- 13.5.2. Non-small Cell Lung Cancer (NSCLC)
- 13.5.3. Pancreatic Cancer
- 13.5.4. Breast Cancer
- 13.5.5. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Type
- 13.7.2. By Route of Administration
- 13.7.3. By Application
- 13.7.4. By Country/Sub-region
14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Key Findings
- 14.3. Market Value Forecast, by Type, 2017-2031
- 14.3.1. Herpes Simplex Virus
- 14.3.2. Vaccinia Virus
- 14.3.3. Adenovirus
- 14.3.4. Reovirus
- 14.3.5. Others
- 14.4. Market Value Forecast, by Route of Administration, 2017-2031
- 14.4.1. Intratumoral
- 14.4.2. Intravenous
- 14.5. Market Value Forecast, by Application, 2017-2031
- 14.5.1. Melanoma
- 14.5.2. Non-small Cell Lung Cancer (NSCLC)
- 14.5.3. Pancreatic Cancer
- 14.5.4. Breast Cancer
- 14.5.5. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Type
- 14.7.2. By Route of Administration
- 14.7.3. By Application
- 14.7.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis, by Company (2022)
- 15.3. Company Profiles
- 15.3.1. Amgen Inc.
- 15.3.1.1. Company Overview
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Merck & Co., Inc. (Viralytics Limited)
- 15.3.2.1. Company Overview
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Shanghai Sunway Biotech Co., Ltd.
- 15.3.3.1. Company Overview
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. TILT Biotherapeutics
- 15.3.4.1. Company Overview
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Oncorus, Inc.
- 15.3.5.1. Company Overview
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Replimune Group, Inc.
- 15.3.6.1. Company Overview
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. Oncolys Biopharma, Inc.
- 15.3.7.1. Company Overview
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Sorrento Therapeutics, Inc.
- 15.3.8.1. Company Overview
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Oncolytics Biotech, Inc.
- 15.3.9.1. Company Overview
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. SillaJen, Inc.
- 15.3.10.1. Company Overview
- 15.3.10.2. Product Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
